Update / Messages
DISCLAIMER
The Diabetes Québec Toolbox is intended for Québec healthcare professionals only. By accessing this web application, you confirm that you are a healthcare professional. The information in the Toolbox is provided for general information purposes only and is not comprehensive. Under no circumstances can Diabetes Québec be held responsible for any error or omission or be prosecuted for any reason whatsoever.

Codes / Indications RAMQ

Summary of EN codes (endocrinology)

When a sulfonylurea is not tolerated or ineffective.
  • • Amaryl®
For the treatment of people with type 2 diabetes:
- As monotherapy when metformin and a sulfonylurea are contraindicated or not tolerated.
  • • Invokana®
  • • Januvia®
  • • Jardiance®
  • • Nesina®
  • • Trajenta®
For the treatment of people with type 2 diabetes:
- In combination with metformin, when a sulfonylurea is contraindicated, not tolerated or ineffective.
  • • Invokana®
  • • Onglyza®
  • • Januvia®
  • • Jardiance®
  • • Nesina®
  • • Forxiga®
  • • Trajenta®
For the treatment of people with type 2 diabetes:
- In combination with a sulfonylurea, when metformin is contraindicated, not tolerated or ineffective.
  • • Invokana®
  • • Onglyza®
  • • Nesina®
  • • Forxiga®
For the treatment of people with type 2 diabetes:
When a sulfonylurea is contraindicated,not tolerated or ineffective; AND
- When the daily doses of metformin have been stable for at least a month.
  • • Janumet®
  • • Janumet®XR
  • • Komboglyze®
  • • Jentadueto🅪
  • • Kazano🅪
  • • Xigduo®
For the treatment of type 2 diabetes, in combination with one or more antidiabetic agents, in persons with a history of atherosclerotic heart disease (ASIC) or atherosclerotic vascular disease (ASK) and whose glycated hemoglobin (HbA1c) is ≥ 7%.
The nature of atherosclerotic heart disease (MCAS) or atherosclerotic vascular disease (MVAS) should be provided upon request by the Régie.
  • • Jardiance®
For the treatment of people with type 2 diabetes whose optimal maximum dose of metformin has been stable for at least one month.
Individuals must also meet the requirements of the recognized indication for the payment of empagliflozin.
  • • Synjardy🅪
Exception Drug Code(FR)
NIHB Canada (Non-Insured Health Benefits)
Drug Benefit List
Patient Exception
Form
Online Request Only
Criteria
  • • Semaglutide Ozempic®
  • • Liraglutide Victoza®
  • • Dulaglutide Trulicity®
  • • Semaglutide Rybelsus®
Reimbursement
(exception drugs)

Ozempic®

For the treatment of people with type 2 diabetes:

  • In combination with metformin, for the treatment of people with type 2 diabetes.
  • When a sulfonylurea is contraindicated, not tolerated or ineffective.
  • Authorization is given for a maximum weekly dose of 1mg.
  • Inefficacy means non-achievement of an HbA1c value tailored to the patient.

To note:

  • Unlike other GLP-1RA (Victoza and Trulicity), your patients do not need to have tried an iDPP4 or have a BMI > 30 to start treatment.
  • Both doses (0.5mg and 1mg) are reimbursed.

Victoza®

For the treatment of people with type 2 diabetes:

  • In combination with metformin, for the treatment of people with type 2 diabetes with inadequate glycemic control and with a body mass index (BMI) above 30 kg/m2.
  • When a DPP-4 inhibitor is contraindicated, not tolerated or ineffective.
  • The maximum duration of each authorization is 12 months.
  • At the time of the first request to extend treatment, the physician is required to provide proof of benefit through a glycosylated hemoglobin (HbA1c) reduction of at least 0.5% or through the achievement of a target value of 7% or less.
  • Authorization is given for a maximum daily dose of 1.8 mg.
  • Inefficacy means non-achievement of an HbA1c value tailored to the patient.

Trulicity®

For the treatment of people with type 2 diabetes:

  • In combination with metformin, for the treatment of people with type 2 diabetes with inadequate glycemic control and with a body mass index (BMI) above 30 kg/m2.
  • When a DPP-4 inhibitor is contraindicated, not tolerated or ineffective.
  • The maximum duration of each authorization is 12 months.
  • At the time of the first request to extend treatment, the physician is required to provide proof of benefit through a glycosylated hemoglobin (HbA1c) reduction of at least 0.5% or through the achievement of a target value of 7% or less.
  • Authorization is given for a maximum daily dose of 1.5 mg.
  • nefficacy means non-achievement of an HbA1c value tailored to the patient.

Rybelsus®

For the treatment of people with type 2 diabetes:

  • In combination with metformin, for the treatment of people with type 2 diabetes.
  • When a sulfonylurea is contraindicated, not tolerated or ineffective.
  • Authorization is given for a maximum daily dose of 14mg.
  • Inefficacy means non-achievement of an HbA1c value tailored to the patient.
Strips
Reimbursement and Coding (FR)
Dexcom G6®
Provincial Coverage and NIHB Eligibilty Criteria for RAMQ
Freestyle Libre™️2
Eligibilty criteria et renewal

Diabetes Screening and Prevention
CANRISK Understanding and preventing type 2 diabetes (DQ)
Evaluation of the Risk of Cardio-Vascular Disease Tool
Patient Questionnaire
Education
Practical Guide for Type 1 Diabetes Management in Adults A Practical Guide to Diabetes Management (DT2 de novo) Low Blood Sugar-hypoglycemia (DQ) High Blood Sugar-hyperglycemia (DQ) Glucagon
Exam Preparation
Colonoscopy (Insulin Matters Program from Sanofi)
Injection Technic FIT Plus
FIT 4th Edition
Sick-Day Management
Jessie Haggai Tool Urinary Tract Infections and Diabetes (DQ) Yeast Infections and Diabetes (DQ)
Cannabis
Diabetes Canada Position Statement
Driving
Driving and Diabetes (DQ)
Mental Health
Ordre des psychologues du Québec Quebec Association for Suicide Prevention Depression and Diabetes (DQ) Stress and Diabetes (DQ) See Digital Applications Tab
Eye Care
Retinopathy Eye Health and Diabetes – Understanding Diabetic Retinopathy (DQ)
Foot Care
AIISPQ (FR) Footcare and diabetes (DQ) Monofilament Testing in the Diabetic Foot Risk Evaluation and Follow-up Plan Tool Rapid Screening for Diabetic Neuropathy Using the 128 Hz Vibration Tuning Fork
Pregnancy
Gestational Diabetes (DQ) Pregnancy and Type 1 Diabetes (DQ) Pregnancy and Type 2 Diabetes (DQ) Screening Interactive Tool (DC)
Ramadan
Diabetes Canada Position Statement Calendar Dates
Diabetes Complications
Nerve Health and Diabetes – Understanding Diabetic Neuropathy (DQ) Kidney Health and Diabetes – Understanding Diabetic Nephropathy (DQ) Heart Health and Diabetes – Understanding Cardiovascular Diseases (DQ)
Miscellaneous
Oral Health and Diabetes – Understanding Periodontal Disease (DQ) Smoking and Diabetes (DQ) Québec sans tabac (J’ARRETE) DM1 (BETTER Program)
Sexuality
Diabète et sexualité féminine (DQ)
Vaccination
Protocole d'immunisation du Québec (PIQ)
Travel
Plan Your Trip Letter of Authorization(DQ) (French) Letter of Authorization(DQ) (English) Letter of Authorization(DQ) (Spanish) Letter of Authorization(DQ) (Chinese)

- How can I add the app to the home screen of my mobile device?

You can add a website icon to your iPhone/iPad Home Screen for quick access. While viewing the website, tap the Share button in the menu bar, then tap Add to Home Screen.

On an Android phone/tablet, use the plus button on the menu and select "Add to home screen"..

- Do I have to download the application to be able to use it?

No. The application is hosted on a server and accessible via a web browser. The technologies used to develop this web application are the same as those used for the creation of websites. You can add a shortcut to the home screen of your mobile device.

- Does the application also work on my computer?

Yes. Although this application targets mobile devices first it will run properly on most modern web browsers (Mac and PC).

- The application does not seem to work normally.

Make sure Javascript is enabled in your device's web browser (usually enabled by default).